BACKGROUND: Until recently, little was known about the costs of the HIV/AIDS epidemic to businesses in Africa or about business responses to the epidemic. This paper synthesizes the results of a set of studies conducted between 1999 and 2006. METHODS: Data for the studies included were drawn from human resource, financial, and medical records of 16 large companies and from 7 surveys of small, medium-sized, and large companies in South Africa, Uganda, Kenya, Zambia, Ethiopia, and Rwanda. RESULTS: Estimated workforce HIV prevalence ranged from 5 to 37%. The average cost per employee lost to AIDS varied from 0.5 to 5.6 times the average annual compensation of the employee affected. Labor cost increases were estimated at 0.6-10.8% but exceeded 3% at only two of 14 companies. Antiretroviral treatment at a cost of US$360/patient per year was found to have positive financial returns for most but not all companies. Managers of small and medium-sized enterprises (SME) reported low AIDS-related employee attrition, little concern about the impacts of AIDS, and relatively little interest in taking action. AIDS was estimated to increase the average operating costs of SME by less than 1%. CONCLUSION: For most companies, AIDS is causing a moderate increase in labor costs, with costs determined mainly by HIV prevalence, employee skill level, and employment policies. Treatment of HIV-positive employees is a good investment for many large companies. Small companies have less capacity to respond to workforce illness and little concern about it. Research on the effectiveness of workplace interventions is needed.
BACKGROUND: Until recently, little was known about the costs of the HIV/AIDS epidemic to businesses in Africa or about business responses to the epidemic. This paper synthesizes the results of a set of studies conducted between 1999 and 2006. METHODS: Data for the studies included were drawn from human resource, financial, and medical records of 16 large companies and from 7 surveys of small, medium-sized, and large companies in South Africa, Uganda, Kenya, Zambia, Ethiopia, and Rwanda. RESULTS: Estimated workforce HIV prevalence ranged from 5 to 37%. The average cost per employee lost to AIDS varied from 0.5 to 5.6 times the average annual compensation of the employee affected. Labor cost increases were estimated at 0.6-10.8% but exceeded 3% at only two of 14 companies. Antiretroviral treatment at a cost of US$360/patient per year was found to have positive financial returns for most but not all companies. Managers of small and medium-sized enterprises (SME) reported low AIDS-related employee attrition, little concern about the impacts of AIDS, and relatively little interest in taking action. AIDS was estimated to increase the average operating costs of SME by less than 1%. CONCLUSION: For most companies, AIDS is causing a moderate increase in labor costs, with costs determined mainly by HIV prevalence, employee skill level, and employment policies. Treatment of HIV-positive employees is a good investment for many large companies. Small companies have less capacity to respond to workforce illness and little concern about it. Research on the effectiveness of workplace interventions is needed.
Authors: Laura M Bogart; Donald Skinner; Idia B Thurston; Yoesrie Toefy; David J Klein; Caroline H Hu; Mark A Schuster Journal: J Adolesc Health Date: 2013-04-06 Impact factor: 5.012
Authors: Pam Sonnenberg; Andrew Copas; Judith R Glynn; Andre Bester; Gill Nelson; Stuart Shearer; Jill Murray Journal: Occup Environ Med Date: 2010-11-28 Impact factor: 4.402
Authors: Fadi El-Jardali; Diana Jamal; Nour Ataya; Maha Jaafar; Saned Raouf; Claudia Matta; Saja Michael; Colette Smith Journal: Health Res Policy Syst Date: 2011-10-07
Authors: M F Olsen; P Kæstel; M Tesfaye; A Abdissa; D Yilma; T Girma; C Mølgaard; D Faurholt-Jepsen; D L Christensen; S Brage; Å B Andersen; H Friis Journal: Epidemiol Infect Date: 2014-06-24 Impact factor: 4.434
Authors: Ingrid de Beer; Hannah M Coutinho; Peter J van Wyk; Esegiel Gaeb; Tobias Rinke de Wit; Michèle van Vugt Journal: J Int AIDS Soc Date: 2009-11-11 Impact factor: 5.396
Authors: Gesine Meyer-Rath; Jan Pienaar; Brian Brink; Andrew van Zyl; Debbie Muirhead; Alison Grant; Gavin Churchyard; Charlotte Watts; Peter Vickerman Journal: PLoS Med Date: 2015-09-01 Impact factor: 11.069